需治疗人数：在恰当背景下的一种临床实用列线图。
The number needed to treat: a clinically useful nomogram in its proper context.
作者信息
Chatellier G, Zapletal E, Lemaitre D, Menard J, Degoulet P
机构信息
Medical Informatics Department, Broussais Hospital, Paris, France.
出版信息
BMJ. 1996 Feb 17;312(7028):426-9. doi: 10.1136/bmj.312.7028.426.
Abstract
The number needed to treat is a meaningful way of expressing the benefit of an active treatment over a control. It can be used either for summarising the results of a therapeutic trial or for medical decision making about an individual patient, but its use at the bedside has been impeded by the need for time consuming calculations. A nomogram has therefore been devised that will greatly simplify the calculations. Since calculations are now easy, the number needed to treat can be used to access the value of several interventions, although it does have its limitations. In particular it should not be used when it is not known whether the relative risk reduction associated with an intervention is constant for all levels of risk, or for periods of time longer than that studied in the original trials.
摘要
需治疗人数是一种表达积极治疗相对于对照治疗益处的有意义方式。它可用于总结治疗试验结果或用于针对个体患者的医疗决策，但由于需要耗时计算，其在床边的应用受到了阻碍。因此设计了一种列线图，将极大地简化计算。由于现在计算变得容易，需治疗人数可用于评估多种干预措施的价值，尽管它确实有其局限性。特别是，当不知道与一种干预措施相关的相对风险降低在所有风险水平或比原始试验研究的时间更长的时间段内是否恒定时，不应使用它。
相似文献
1
The number needed to treat: a clinically useful nomogram in its proper context.需治疗人数：在恰当背景下的一种临床实用列线图。
BMJ. 1996 Feb 17;312(7028):426-9. doi: 10.1136/bmj.312.7028.426.
2
Number needed to treat (or harm).需治疗（或伤害）人数。
World J Surg. 2005 May;29(5):576-81. doi: 10.1007/s00268-005-7916-8.
3
The need for endpoints in anticancer drug trials that will simplify the clinical decision-making process.
Eur J Cancer. 1997 Jan;33 Suppl 2:S11-3. doi: 10.1016/s0959-8049(96)00448-0.
4
Decision making in surgical treatment of chronic low back pain: the performance of prognostic tests to select patients for lumbar spinal fusion.慢性下腰痛手术治疗中的决策：用于选择腰椎融合术患者的预后测试的效能
Acta Orthop Suppl. 2013 Feb;84(349):1-35. doi: 10.3109/17453674.2012.753565.
5
The number needed to treat: a clinically useful measure of treatment effect.需治疗人数：一种临床实用的治疗效果衡量指标。
BMJ. 1995 Feb 18;310(6977):452-4. doi: 10.1136/bmj.310.6977.452.
6
Personalised risk communication for informed decision making about taking screening tests.关于进行筛查测试的明智决策的个性化风险沟通。
Cochrane Database Syst Rev. 2006 Oct 18(4):CD001865. doi: 10.1002/14651858.CD001865.pub2.
7
Adjusting the number needed to treat: incorporating adjustments for the utility and timing of benefits and harms.
Med Decis Making. 1993 Jul-Sep;13(3):247-52. doi: 10.1177/0272989X9301300312.
8
Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke.急性缺血性脑卒中动脉内脑溶栓的试验设计与报告标准。
Stroke. 2003 Aug;34(8):e109-37. doi: 10.1161/01.STR.0000082721.62796.09. Epub 2003 Jul 17.
9
Number needed to treat: a descriptor for weighing therapeutic options.
Am J Health Syst Pharm. 2005 Oct 1;62(19):2031-6. doi: 10.2146/ajhp040558.
10
Risk prediction of hepatotoxicity in paracetamol poisoning.对乙酰氨基酚中毒时肝毒性的风险预测
Clin Toxicol (Phila). 2017 Sep;55(8):879-892. doi: 10.1080/15563650.2017.1317349. Epub 2017 Apr 27.
引用本文的文献
1
Randomized controlled trial of intrauterine cephapirin treatment in cows of 100 days in milk or more affected by reproductive tract diseases.对产奶100天及以上且患有生殖道疾病的奶牛进行宫内头孢匹林治疗的随机对照试验。
JDS Commun. 2025 Jan 10;6(3):378-382. doi: 10.3168/jdsc.2024-0691. eCollection 2025 May.
2
Building bridges from research outcomes to clinical practice decisions.搭建从研究成果到临床实践决策的桥梁。
Angle Orthod. 2025 Mar 1;95(2):141-148. doi: 10.2319/Bridges_edited-11-23-24.1.
3
Assessment of the onset of analgesia and length of analgesia following the use of PBM with different wavelengths: a clinical study.不同波长 PBM 治疗后镇痛起效时间和镇痛持续时间的评估：一项临床研究。
Lasers Med Sci. 2024 Sep 19;39(1):236. doi: 10.1007/s10103-024-04184-y.
4
Estimated Number Needed to Treat to Avoid a First Hospitalization by Maintaining Instead of Reducing Renin-Angiotensin-Aldosterone System Inhibitor (RAASi) Therapy after Hyperkalemia.高钾血症后维持而非减少肾素-血管紧张素-醛固酮系统抑制剂（RAASi）治疗以避免首次住院所需的估计治疗人数。
Kidney360. 2024 Dec 1;5(12):1813-1823. doi: 10.34067/KID.0000000000000561. Epub 2024 Aug 21.
5
Evaluation of an Intensive Suicide- Reattempt–Prevention Programme based on Problem-Solving Therapy in a Catchment Area of 430,000 people in Madrid, Spain.评估基于问题解决治疗的密集自杀-再尝试预防计划在西班牙马德里 43 万人口的流域地区的应用。
Actas Esp Psiquiatr. 2022 May;50(3):134-143. Epub 2022 May 1.
6
Decreased mortality and increased side effects in COVID-19 patients treated with IL-6 receptor antagonists: systematic review and meta-analysis.COVID-19 患者接受白细胞介素 6 受体拮抗剂治疗后死亡率降低且副作用增加：系统评价和荟萃分析。
Sci Rep. 2021 Nov 2;11(1):21522. doi: 10.1038/s41598-021-00726-4.
7
Real-world Effectiveness and Tolerability of Monoclonal Antibody Therapy for Ambulatory Patients With Early COVID-19.单克隆抗体疗法对早期COVID-19门诊患者的真实世界有效性和耐受性
Open Forum Infect Dis. 2021 Jun 23;8(7):ofab331. doi: 10.1093/ofid/ofab331. eCollection 2021 Jul.
8
Functional outcomes with Carillon device over 1 year in patients with functional mitral regurgitation of Grades 2+ to 4+: results from the REDUCE-FMR trial.在2+至4+级功能性二尖瓣反流患者中使用Carillon装置超过1年的功能结局：REDUCE-FMR试验结果
ESC Heart Fail. 2021 Apr;8(2):872-878. doi: 10.1002/ehf2.13273. Epub 2021 Feb 22.
9
Development and Validation of a Prognostic Nomogram to Predict the Long-Time Prognosis in Non-B, Non-C Hepatocellular Carcinoma.预测非B、非C型肝细胞癌长期预后的预后列线图的开发与验证
Cancer Manag Res. 2020 Aug 24;12:7771-7781. doi: 10.2147/CMAR.S257016. eCollection 2020.
10
Cost-utility, cost-effectiveness, and budget impact of Internet-based cognitive behavioral therapy for breast cancer survivors with treatment-induced menopausal symptoms.基于互联网的认知行为疗法治疗乳腺癌治疗后更年期症状患者的成本-效用、成本效果和预算影响。
Breast Cancer Res Treat. 2019 Dec;178(3):573-585. doi: 10.1007/s10549-019-05410-w. Epub 2019 Aug 26.
本文引用的文献
1
Do physicians estimate reliably the cardiovascular risk of hypertensive patients?
Medinfo. 1995;8 Pt 2:876-9.
2
Beta-blockers after myocardial infarction: influence of first-year clinical course on long-term effectiveness.心肌梗死后使用β受体阻滞剂：第一年临床病程对长期疗效的影响。
Ann Intern Med. 1993 Jan 15;118(2):99-105. doi: 10.7326/0003-4819-118-2-199301150-00004.
3
A population-based study of the risk of recurrence of birth defects.一项基于人群的出生缺陷复发风险研究。
N Engl J Med. 1994 Jul 7;331(1):1-4. doi: 10.1056/NEJM199407073310101.
4
Influence of method of reporting study results on decision of physicians to prescribe drugs to lower cholesterol concentration.研究结果报告方式对医生开具降低胆固醇浓度药物决策的影响。
BMJ. 1994 Sep 24;309(6957):761-4. doi: 10.1136/bmj.309.6957.761.
5
Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration.冠状动脉搭桥手术对生存率的影响：冠状动脉搭桥手术试验协作组随机试验10年结果概述
Lancet. 1994 Aug 27;344(8922):563-70. doi: 10.1016/s0140-6736(94)91963-1.
6
The number needed to treat: a clinically useful measure of treatment effect.需治疗人数：一种临床实用的治疗效果衡量指标。
BMJ. 1995 Feb 18;310(6977):452-4. doi: 10.1136/bmj.310.6977.452.
7
Do doctors accurately assess coronary risk in their patients? Preliminary results of the coronary health assessment study.医生能否准确评估患者的冠心病风险？冠心病健康评估研究的初步结果。
BMJ. 1995 Apr 15;310(6985):975-8. doi: 10.1136/bmj.310.6985.975.
8
An assessment of clinically useful measures of the consequences of treatment.对治疗后果的临床有用测量方法的评估。
N Engl J Med. 1988 Jun 30;318(26):1728-33. doi: 10.1056/NEJM198806303182605.
9
Cardiovascular disease risk profiles.心血管疾病风险概况。
Am Heart J. 1991 Jan;121(1 Pt 2):293-8. doi: 10.1016/0002-8703(91)90861-b.
10
Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context.血压、中风与冠心病。第2部分，血压的短期降低：在流行病学背景下随机药物试验综述
Lancet. 1990 Apr 7;335(8693):827-38. doi: 10.1016/0140-6736(90)90944-z.
Zotero 插件